Sangamo Therapeutics, Inc. last reported quarterly results on May 14, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): revenue of $1.4 million (-77.6% year over year) and diluted EPS of -$0.08. It usually reports 34–44 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
May 14, 2026
44 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1
-77.6%
|
-31
-1.3%
|
-0.08
+42.9%
|
|
Feb 3, 2026
34 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
14
+88.4%
|
-37
-59.9%
|
-0.11
+0.4%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
-98.8%
|
-35
-427.3%
|
-0.11
-375.0%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
18
+5042.1%
|
-20
+44.7%
|
-0.08
+55.6%
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
49
+425.8%
|
11
+110.2%
|
0.04
+106.8%
|
|
Aug 6, 2024
37 days after quarter end
|
Q2 FY2024
ended Jun 30, 2024
|
0
-94.8%
|
-36
+68.4%
|
-0.18
+72.7%
|
|
May 9, 2024
39 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Mar 13, 2024
73 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SGMOQ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Richmond, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1001233
- Former names
- SANGAMO BIOSCIENCES INC (until Jan 6, 2017)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.